497 related articles for article (PubMed ID: 27820973)
1. Emerging biological therapies to treat acute lymphoblastic leukemia.
Huguet F; Tavitian S
Expert Opin Emerg Drugs; 2017 Mar; 22(1):107-121. PubMed ID: 27820973
[TBL] [Abstract][Full Text] [Related]
2. Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.
Valecha GK; Ibrahim U; Ghanem S; Asti D; Atallah JP; Terjanian T
Expert Rev Hematol; 2017 Sep; 10(9):783-799. PubMed ID: 28666090
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia.
Hoelzer D
Curr Opin Oncol; 2013 Nov; 25(6):701-6. PubMed ID: 24097105
[TBL] [Abstract][Full Text] [Related]
4. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
[TBL] [Abstract][Full Text] [Related]
5. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia.
Farhadfar N; Litzow MR
Leuk Res; 2016 Oct; 49():13-21. PubMed ID: 27521873
[TBL] [Abstract][Full Text] [Related]
6. [Treatment response of a two-dose regimen of dose-adjusted inotuzumab ozogamicin in relapsed/refractory B-cell acute lymphoblastic leukemia].
An LL; Zhao DF; Hou RF; Guan HH; Yan H; Lin YH; Tong CR; Wu T; Liu SY
Zhonghua Xue Ye Xue Za Zhi; 2023 Nov; 44(11):911-916. PubMed ID: 38185520
[No Abstract] [Full Text] [Related]
7. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
[TBL] [Abstract][Full Text] [Related]
8. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.
Jabbour E; Short NJ; Jain N; Haddad FG; Welch MA; Ravandi F; Kantarjian H
J Hematol Oncol; 2023 Mar; 16(1):22. PubMed ID: 36927623
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
Ribera JM
Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
[TBL] [Abstract][Full Text] [Related]
10. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.
Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833
[TBL] [Abstract][Full Text] [Related]
11. Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia.
Le Jeune C; Thomas X
Eur J Haematol; 2015 Feb; 94(2):99-108. PubMed ID: 24981395
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies in acute lymphoblastic leukemia.
Jabbour E; O'Brien S; Ravandi F; Kantarjian H
Blood; 2015 Jun; 125(26):4010-6. PubMed ID: 25999456
[TBL] [Abstract][Full Text] [Related]
13. Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy.
Qi Y; Liu H; Li X; Shi Y; Mu J; Li J; Wang Y; Deng Q
Ann Med; 2023 Dec; 55(1):2230888. PubMed ID: 37417690
[TBL] [Abstract][Full Text] [Related]
14. Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia.
Wei G; Wang J; Huang H; Zhao Y
J Hematol Oncol; 2017 Aug; 10(1):150. PubMed ID: 28821272
[TBL] [Abstract][Full Text] [Related]
15. Comparing the efficacy of salvage regimens for relapsed/refractory B-cell acute lymphoblastic leukaemia: a systematic review and network meta-analysis.
Cao HY; Wan CL; Xue SL
Ann Hematol; 2023 Jan; 102(1):155-165. PubMed ID: 36394582
[TBL] [Abstract][Full Text] [Related]
16. Antibody therapy for acute lymphoblastic leukemia.
Portell CA; Advani AS
Curr Hematol Malig Rep; 2012 Jun; 7(2):153-9. PubMed ID: 22422550
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy approaches to treat adult acute lymphoblastic leukemia.
Maino E; Bonifacio M; Scattolin AM; Bassan R
Expert Rev Hematol; 2016 Jun; 9(6):563-77. PubMed ID: 27011303
[TBL] [Abstract][Full Text] [Related]
18. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.
Le Jeune C; Thomas X
Drug Des Devel Ther; 2016; 10():757-65. PubMed ID: 26937176
[TBL] [Abstract][Full Text] [Related]
19. A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions.
Halford Z; Coalter C; Gresham V; Brown T
Ann Pharmacother; 2021 Oct; 55(10):1236-1253. PubMed ID: 33435716
[TBL] [Abstract][Full Text] [Related]
20. [Antibody therapy for acute lymphoblastic leukemia].
Hatta Y
Rinsho Ketsueki; 2020; 61(8):922-928. PubMed ID: 32908056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]